Shilpa Medicare delivered exceptional Q4 FY26 results with consolidated net profit attributable to owners more than doubling to ₹10,088 lakhs from ₹4,688 lakhs in Q4 FY25, representing 115% year-on-year growth. The company has set September 4, 2026 as the record date for its FY26 final dividend, subject to shareholder approval at the AGM on September 11, 2026. Consolidated revenue from operations rose to ₹46,578 lakhs from ₹32,147 lakhs in the corresponding quarter of the previous year, marking 45% growth. On a standalone basis, net profit increased significantly to ₹6,492 lakhs from ₹1,871 lakhs, with standalone revenue nearly doubling to ₹18,904 lakhs from ₹9,346 lakhs. The growth was partly driven by a one-time deferred tax liability reversal of ₹2,684 lakhs following a reassessment under the new tax regime.
The API business showed robust performance with revenue growing approximately 15% YoY to ₹260 crore, contributing 47% of total revenue. The formulations segment emerged as the key growth driver, more than doubling with 102.04% YoY growth to ₹198 crore, contributing 42% of total revenue. The biologics business generated ₹52 crore in revenue during Q1 FY27, contributing 11% of total revenue. The company's Specialty CDMO division continued to see strong traction, driven by new client acquisitions in developed markets. The Novel products business doubled from the same quarter last year, with excluding licensing income, revenue growth standing at 112%.
European formulations revenue stood at ₹57 crore, showing 84% growth from the previous year, led by continued portfolio expansion and market penetration. The domestic formulations business grew by 179% from the year-ago period. According to the company's investor presentation, the strong performance across international markets reflects successful market expansion strategies and effective portfolio management.
The Board approved an investment of up to EUR 7 million by its wholly owned subsidiary, Shilpa Biocare Private Limited, in Gate2Brain (G2B) through a combination of cash infusion, equity for services, and project development, marking a strategic long-term equity partnership. The company appointed Dr. Uday N. Harle as CEO of subsidiary Shilpa Biologicals effective August 3, 2026, strengthening leadership for the biologics division. Additionally, India Ratings & Research assigned a credit rating of IND A+/Stable/IND A1+ to Shilpa Biologicals' ₹125 crore bank loan facilities in July 2026, reflecting improved financial stability. The Board also sanctioned the Scheme of Merger by Absorption of Shilpa Therapeutics Private Limited, with financials restated accordingly.
The 39th AGM is scheduled for September 11, 2026 via video conferencing at 11:00 AM, with remote e-voting commencing on September 7, 2026, and concluding on September 10, 2026. M/s KFin Technologies Limited has been engaged to facilitate the e-voting process. Shares of Shilpa Medicare surged 11.59% to ₹723.55 after the record-breaking results announcement, hitting a fresh all-time high after the strong Q1 performance. The stock has delivered impressive returns with 127% growth for the year so far, reflecting strong investor confidence in the company's growth trajectory and operational performance. Historical stock returns show 130.52% growth over one year and 131.11% over five years.
